Mirzasna (Mirtazapine)

Mirtazapine, the active ingredient in Mirzasna, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as an unknown strength/oral tablet for oral use. It is indicated for the treatment of major depressive disorder in adults. GNH USA supplies Mirzasna as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirtazapine acts on central neurotransmitter pathways to alleviate depressive symptoms. - Major depressive disorder: reduces depressive mood, improves sleep and appetite, and enhances overall functioning.

Mirtazapine may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Sedation or drowsiness: feeling unusually sleepy, especially at treatment start. - Increased appetite and weight gain: heightened hunger leading to weight increase. - Dry mouth: reduced salivation causing oral discomfort. - Constipation: slowed gastrointestinal transit. - Dizziness: light‑headed sensation, particularly when standing quickly. - Edema: mild swelling of ankles or feet.

Serious or Rare Side Effects: - Agranulocytosis: severe reduction in white blood cells, increasing infection risk. - Seizures: occurrence of convulsive episodes. - Severe hypersensitivity: rash, itching, swelling, or difficulty breathing. - Hepatotoxicity: signs of liver injury such as jaundice. - Suicidal thoughts: emergence or worsening of suicidal ideation. - Hyponatremia: low blood sodium causing confusion or weakness.

Before initiating therapy, consider the following safety measures. - Pregnancy: discuss potential risks with a healthcare professional; data are limited. - Breastfeeding: evaluate benefits versus risks, as drug may pass into milk. - Elderly patients: start at lower doses and monitor for sedation and falls. - Hepatic impairment: dose adjustment may be required; monitor liver function. - Concomitant CNS depressants: avoid excessive sedation by adjusting doses. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Mirtazapine can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - MAO inhibitors: risk of serotonin syndrome; discontinue MAOI at least 14 days prior. - CNS depressants (e.g., benzodiazepines, alcohol): may cause profound sedation or respiratory depression.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): may enhance bleeding risk; monitor INR. - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): can increase mirtazapine plasma levels. - Anticholinergic agents: additive dry mouth and constipation. - Lithium: may increase risk of neurotoxicity; monitor lithium levels.